(b) Sarepta therapeutics announces fda accelerated approval of exondys 51™ (eteplirsen) injection, an exon skipping therapy to treat duchenne muscular dystrophy (dmd) patients amenable to skipping exon 51. (c) The Resolve™ trial, a Phase 3 trial of our RSV F Vaccine in 11,856 older ...
PURPOSE: To evaluate the safety of an HER-2/neu intracellular domain (ICD) protein vaccine and to estimate whether vaccine dose impacts immunogenicity. PAT... ML Disis,K Schiffman,K Guthrie,... - 《Journal of Clinical Oncology》 被引量: 400发表: 2004年 Immunologic correlates of protection in...
molecules Review Application of Nanomaterials to Enhance Polymerase Chain Reaction Zhu Yang 1,2, Bei Shen 3, Lihuan Yue 3,4, Yuqing Miao 1,*, Yihong Hu 3,* and Ruizhuo Ouyang 1,* 1 Institute of Bismuth and Rhenium Science, School Materials and Chemistry, University of Shanghai for ...